AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RLYB
  4. [8-K] Rallybio Corporation Reports Material Event

[8-K] Rallybio Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Rallybio (NASDAQ:RLYB) filed an 8-K announcing a new employment agreement with Chief Medical Officer Steven Ryder, M.D.

Key terms

  • Base salary: $531,227
  • Annual target bonus: 40% of salary
  • Initial one-year term with automatic one-year renewals
  • Standard severance: 12 months salary, prior bonus and up to 12 months COBRA
  • Change-in-control severance: 1.5脳 salary + target bonus, 18 months COBRA and full vesting of time-based equity

Severance requires a release of claims; a 12-month non-compete and non-solicitation applies. No other operational or financial updates were disclosed.

Rallybio (NASDAQ:RLYB) ha presentato un modulo 8-K per annunciare un nuovo contratto di lavoro con il Chief Medical Officer Steven Ryder, M.D.

Termini principali

  • Salario base: 531.227 $
  • Bonus annuale target: 40% del salario
  • Durata iniziale di un anno con rinnovi automatici di un anno
  • Indennit脿 standard: 12 mesi di salario, bonus precedente e fino a 12 mesi di COBRA
  • Indennit脿 in caso di cambio di controllo: 1,5脳 il salario + bonus target, 18 mesi di COBRA e pieno consolidamento delle azioni basate sul tempo

L'indennit脿 richiede una rinuncia a eventuali reclami; si applica un vincolo di non concorrenza e non sollecitazione per 12 mesi. Non sono stati forniti altri aggiornamenti operativi o finanziari.

Rallybio (NASDAQ:RLYB) present贸 un formulario 8-K anunciando un nuevo contrato laboral con el Director M茅dico Steven Ryder, M.D.

T茅rminos clave

  • Salario base: 531,227 $
  • Bono anual objetivo: 40% del salario
  • Plazo inicial de un a帽o con renovaciones autom谩ticas de un a帽o
  • Indemnizaci贸n est谩ndar: 12 meses de salario, bono previo y hasta 12 meses de COBRA
  • Indemnizaci贸n por cambio de control: 1.5脳 salario + bono objetivo, 18 meses de COBRA y consolidaci贸n total de acciones basadas en tiempo

La indemnizaci贸n requiere una renuncia a reclamaciones; se aplica una cl谩usula de no competencia y no captaci贸n por 12 meses. No se divulgaron otras actualizaciones operativas o financieras.

Rallybio (NASDAQ:RLYB)電� 斓滉碃 鞚橂 毂呾瀯鞛� Steven Ryder, M.D.鞕�鞚� 靸堧鞖� 瓿犾毄 瓿勳暯鞚� 氚滍憸頃橂姅 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.

欤检殧 臁瓣贝

  • 旮半掣 旮夓棳: $531,227
  • 鞐瓣皠 氇╉憸 氤措剤鞀�: 旮夓棳鞚� 40%
  • 齑堦赴 1雲� 瓿勳暯 旮瓣皠, 鞛愲彊 1雲� 臧膘嫚
  • 響滌 韲挫旮�: 12臧滌洈 旮夓棳, 鞚挫爠 氤措剤鞀� 氚� 斓滊寑 12臧滌洈 COBRA
  • 瓴届榿甓� 氤�瓴� 鞁� 韲挫旮�: 旮半掣旮夓潣 1.5氚� + 氇╉憸 氤措剤鞀�, 18臧滌洈 COBRA 氚� 鞁滉皠 旮半皹 欤检嫕 鞕勳爠 氩犾姢韺�

韲挫旮� 歆�旮夓潃 觳惮甓� 韽赴毳� 鞖旉惮頃橂┌, 12臧滌洈臧� 瓴届焷 旮堨 氚� 鞙犾澑 旮堨 臁绊暛鞚� 鞝侅毄霅╇媹雼�. 旮绊儉 鞖挫榿 霕愲姅 鞛 鞐呺嵃鞚错姼電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Rallybio (NASDAQ:RLYB) a d茅pos茅 un formulaire 8-K annon莽ant un nouvel accord d'emploi avec le Chief Medical Officer Steven Ryder, M.D.

Principaux termes

  • Salaire de base : 531 227 $
  • Bonus annuel cible : 40% du salaire
  • Dur茅e initiale d'un an avec renouvellements automatiques d'un an
  • Indemnit茅 de d茅part standard : 12 mois de salaire, bonus ant茅rieur et jusqu'脿 12 mois de COBRA
  • Indemnit茅 en cas de changement de contr么le : 1,5脳 le salaire + bonus cible, 18 mois de COBRA et acquisition compl猫te des actions bas茅es sur le temps

L'indemnit茅 n茅cessite une renonciation aux r茅clamations ; une clause de non-concurrence et de non-sollicitation de 12 mois s'applique. Aucune autre mise 脿 jour op茅rationnelle ou financi猫re n'a 茅t茅 divulgu茅e.

Rallybio (NASDAQ:RLYB) hat eine 8-K Meldung eingereicht, in der eine neue Anstellung mit Chief Medical Officer Steven Ryder, M.D. bekannt gegeben wird.

Wesentliche Bedingungen

  • Grundgehalt: 531.227 $
  • J盲hrlicher Zielbonus: 40% des Gehalts
  • Anf盲ngliche Laufzeit von einem Jahr mit automatischer Verl盲ngerung um jeweils ein Jahr
  • Standardabfindung: 12 Monate Gehalt, vorheriger Bonus und bis zu 12 Monate COBRA
  • Abfindung bei Kontrollwechsel: 1,5脳 Gehalt + Zielbonus, 18 Monate COBRA und vollst盲ndige Vesting von zeitabh盲ngigen Aktien

Die Abfindung erfordert einen Verzicht auf Anspr眉che; eine 12-monatige Wettbewerbs- und Abwerbeverbotsklausel gilt. Weitere operative oder finanzielle Updates wurden nicht bekannt gegeben.

Positive
  • Continuity of leadership: Contract secures experienced CMO through automatic renewals, supporting execution of key clinical trials.
Negative
  • Increased potential cash obligation: Change-in-control package could cost shareholders over $1 million plus accelerated equity vesting.

Insights

TL;DR: Contract locks in CMO retention; costs modest but rise on CIC.

The agreement standardizes pay and incentives, aligning Ryder with peers while limiting immediate dilution. CIC terms鈥�1.5脳 cash plus full equity鈥攁dd roughly $1.1 million in potential outlays, manageable for a small-cap biotech but slightly richer than median. Non-compete and release provisions protect corporate IP and mitigate litigation risk. Overall impact is balanced: continuity for critical clinical leadership versus incremental cost exposure.

TL;DR: Governance-friendly structure, though payout multiple above ISS median.

Board obtained a one-year rolling term鈥攔educing multi-year lock-in鈥攚hile securing a 12-month post-employment non-compete. Cash severance multiple (1.5脳) exceeds typical 1脳 but stays below red-flag 3脳 thresholds. Equity acceleration limited to time-based awards aligns with best practices. No gross-up clauses appear. Investors should monitor aggregate CIC liabilities as additional executives adopt similar templates.

Rallybio (NASDAQ:RLYB) ha presentato un modulo 8-K per annunciare un nuovo contratto di lavoro con il Chief Medical Officer Steven Ryder, M.D.

Termini principali

  • Salario base: 531.227 $
  • Bonus annuale target: 40% del salario
  • Durata iniziale di un anno con rinnovi automatici di un anno
  • Indennit脿 standard: 12 mesi di salario, bonus precedente e fino a 12 mesi di COBRA
  • Indennit脿 in caso di cambio di controllo: 1,5脳 il salario + bonus target, 18 mesi di COBRA e pieno consolidamento delle azioni basate sul tempo

L'indennit脿 richiede una rinuncia a eventuali reclami; si applica un vincolo di non concorrenza e non sollecitazione per 12 mesi. Non sono stati forniti altri aggiornamenti operativi o finanziari.

Rallybio (NASDAQ:RLYB) present贸 un formulario 8-K anunciando un nuevo contrato laboral con el Director M茅dico Steven Ryder, M.D.

T茅rminos clave

  • Salario base: 531,227 $
  • Bono anual objetivo: 40% del salario
  • Plazo inicial de un a帽o con renovaciones autom谩ticas de un a帽o
  • Indemnizaci贸n est谩ndar: 12 meses de salario, bono previo y hasta 12 meses de COBRA
  • Indemnizaci贸n por cambio de control: 1.5脳 salario + bono objetivo, 18 meses de COBRA y consolidaci贸n total de acciones basadas en tiempo

La indemnizaci贸n requiere una renuncia a reclamaciones; se aplica una cl谩usula de no competencia y no captaci贸n por 12 meses. No se divulgaron otras actualizaciones operativas o financieras.

Rallybio (NASDAQ:RLYB)電� 斓滉碃 鞚橂 毂呾瀯鞛� Steven Ryder, M.D.鞕�鞚� 靸堧鞖� 瓿犾毄 瓿勳暯鞚� 氚滍憸頃橂姅 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟.

欤检殧 臁瓣贝

  • 旮半掣 旮夓棳: $531,227
  • 鞐瓣皠 氇╉憸 氤措剤鞀�: 旮夓棳鞚� 40%
  • 齑堦赴 1雲� 瓿勳暯 旮瓣皠, 鞛愲彊 1雲� 臧膘嫚
  • 響滌 韲挫旮�: 12臧滌洈 旮夓棳, 鞚挫爠 氤措剤鞀� 氚� 斓滊寑 12臧滌洈 COBRA
  • 瓴届榿甓� 氤�瓴� 鞁� 韲挫旮�: 旮半掣旮夓潣 1.5氚� + 氇╉憸 氤措剤鞀�, 18臧滌洈 COBRA 氚� 鞁滉皠 旮半皹 欤检嫕 鞕勳爠 氩犾姢韺�

韲挫旮� 歆�旮夓潃 觳惮甓� 韽赴毳� 鞖旉惮頃橂┌, 12臧滌洈臧� 瓴届焷 旮堨 氚� 鞙犾澑 旮堨 臁绊暛鞚� 鞝侅毄霅╇媹雼�. 旮绊儉 鞖挫榿 霕愲姅 鞛 鞐呺嵃鞚错姼電� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Rallybio (NASDAQ:RLYB) a d茅pos茅 un formulaire 8-K annon莽ant un nouvel accord d'emploi avec le Chief Medical Officer Steven Ryder, M.D.

Principaux termes

  • Salaire de base : 531 227 $
  • Bonus annuel cible : 40% du salaire
  • Dur茅e initiale d'un an avec renouvellements automatiques d'un an
  • Indemnit茅 de d茅part standard : 12 mois de salaire, bonus ant茅rieur et jusqu'脿 12 mois de COBRA
  • Indemnit茅 en cas de changement de contr么le : 1,5脳 le salaire + bonus cible, 18 mois de COBRA et acquisition compl猫te des actions bas茅es sur le temps

L'indemnit茅 n茅cessite une renonciation aux r茅clamations ; une clause de non-concurrence et de non-sollicitation de 12 mois s'applique. Aucune autre mise 脿 jour op茅rationnelle ou financi猫re n'a 茅t茅 divulgu茅e.

Rallybio (NASDAQ:RLYB) hat eine 8-K Meldung eingereicht, in der eine neue Anstellung mit Chief Medical Officer Steven Ryder, M.D. bekannt gegeben wird.

Wesentliche Bedingungen

  • Grundgehalt: 531.227 $
  • J盲hrlicher Zielbonus: 40% des Gehalts
  • Anf盲ngliche Laufzeit von einem Jahr mit automatischer Verl盲ngerung um jeweils ein Jahr
  • Standardabfindung: 12 Monate Gehalt, vorheriger Bonus und bis zu 12 Monate COBRA
  • Abfindung bei Kontrollwechsel: 1,5脳 Gehalt + Zielbonus, 18 Monate COBRA und vollst盲ndige Vesting von zeitabh盲ngigen Aktien

Die Abfindung erfordert einen Verzicht auf Anspr眉che; eine 12-monatige Wettbewerbs- und Abwerbeverbotsklausel gilt. Weitere operative oder finanzielle Updates wurden nicht bekannt gegeben.

0001739410false00017394102025-06-252025-06-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________
FORM 8-K
______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 25, 2025
______________________________________________________
RALLYBIO CORPORATION
(Exact name of Registrant as Specified in Its Charter)
______________________________________________________
Delaware001-4069385-1083789
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
234 Church Street, Suite 1020 New Haven, Connecticut
06510
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 203 859-3820
(Former Name or Former Address, if Changed Since Last Report)
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per shareRLYBNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 25, 2025, Rallybio Corporation (Rallybio) entered into an employment agreement (the Employment Agreement) with Steven Ryder, M.D., Rallybio’s Chief Medical Officer. Dr. Ryder has served as Rallybio’s Chief Medical Officer since January 2019.

Pursuant to the Employment Agreement, Dr. Ryder will receive an initial annual base salary of $531,227 per year. Under the terms of the Employment Agreement, Dr. Ryder will be eligible to receive an annual target bonus of up to 40% of his base salary based on achievement of individual and/or company annual performance goals, as set by the Board of Directors of Rallybio (the Board) or the Compensation Committee of the Board. Dr. Ryder will serve for an initial one-year term, which term will automatically extend for successive one-year terms unless either Rallybio or Dr. Ryder elects to not extend the term by giving the other party at least 60 days’ notice prior to the end of the current term.

Pursuant to the Employment Agreement, Dr. Ryder is entitled to severance payments and benefits in connection with certain qualifying terminations of employment. If Dr. Ryder’s employment is terminated by Rallybio without cause, as a result of Rallybio’s non-extension of the employment term or by Dr. Ryder for good reason, as defined in the Employment Agreement, he will be entitled to receive (i) any earned and payable, but unpaid, annual bonus for a calendar year ending on or preceding the date of termination, (ii) continued payment of his annual base salary for a period of 12 months following termination and (iii) subject to his timely election of COBRA coverage, payment of a monthly amount equal to the monthly health premiums paid by Rallybio on behalf of Dr. Ryder and his eligible dependents for 12 months following termination (or, if earlier, until such time as Dr. Ryder ceases to be eligible for COBRA coverage or obtains health coverage from another employer). If Dr. Ryder’s employment is terminated by reason of his death or disability, he will be entitled to receive (i) any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the termination occurs on the last day of the calendar year) and (ii) continued payment of his annual base salary for a period of six months following termination.

If Dr. Ryder’s employment is terminated by Rallybio without cause, as a result of Rallybio’s non-extension of the employment term or by Dr. Ryder for good reason, as defined in the Employment Agreement, in each case within the 12-month period following a change in control, in lieu of the severance payments and benefits described above, he will be entitled to receive (i) any earned and payable, but unpaid, prior year annual bonus (or current year bonus if the termination occurs on the last day of the calendar year), (ii) an amount equal to 1.5 times the sum of his annual base salary and target annual bonus, payable over 18 months following termination and (iii) subject to his timely election of COBRA coverage, payment of a monthly amount equal to the monthly health premiums paid by Rallybio on his behalf and his eligible dependents for 18 months following termination (or, if earlier, until such time as the executive officer ceases to be eligible for COBRA coverage or obtains health coverage from another employer). In addition, any outstanding and unvested equity awards, the vesting of which is based only on the passage of time, held by Dr. Ryder as of the date of termination shall vest in full immediately prior to such termination of employment.

Rallybio’s obligation to provide severance payments and other benefits under the Employment Agreement is conditioned on Dr. Ryder signing a release of claims in favor of Rallybio. Under the Employment Agreement, Dr. Ryder has agreed that during his employment and for one year following his termination of employment he will not compete with Rallybio or its affiliates or solicit Rallybio’s or its affiliates customers, employees, representatives, agents, vendors, joint venturers or licensors.

The foregoing description of the Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Employment Agreement, a copy of which Rallybio is filed with this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit No.Description
10.1
Employment Agreement, by and between Rallybio, LLC, Rallybio Corporation and Steven Ryder, dated as of June 25, 2025


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
RALLYBIO CORPORATION
Date:June 27, 2025By:/s/ Jonathan I. Lieber
Jonathan I. Lieber
Chief Financial Officer and Treasurer

Source:

FAQ

What is RLYB's new base salary for Chief Medical Officer Steven Ryder?

The 8-K states Dr. Ryder will earn a $531,227 annual base salary effective June 25 2025.

How large is Dr. Ryder's target bonus under Rallybio's 2025 employment agreement?

He is eligible for an annual bonus of up to 40% of base salary, contingent on performance goals.

What severance does Dr. Ryder receive if terminated without cause at Rallybio?

He would receive 12 months of continued base salary, any earned bonus and up to 12 months paid COBRA premiums.

How does a change-in-control affect Dr. Ryder's payout?

If terminated within 12 months of a change-in-control, he is entitled to 1.5脳 salary + target bonus, 18 months COBRA and full vesting of time-based equity.

Does the agreement include non-compete restrictions for Dr. Ryder?

Yes. He is barred from competing with Rallybio and from soliciting its employees or customers for one year after departure.
Stock RLYB logo
Rallybio Corp

NASDAQ:RLYB

RLYB Rankings

#8323 Ranked by Market Cap
N/A Ranked by Dividends
#11 Top Gainer

RLYB Latest News

Jul 8, 2025
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Jun 12, 2025
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
May 8, 2025
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Apr 29, 2025
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
Apr 8, 2025
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

RLYB Latest SEC Filings

Jul 8, 2025
[8-K] Rallybio Corporation Reports Material Event

RLYB Stock Data

14.07M
36.86M
4.05%
77.11%
0.81%
Biotechnology
Pharmaceutical Preparations
United States
NEW HAVEN